Green Cross Medical Science Corporation
Green Cross Medical Science Corporation manufactures and sells diagnostic reagents and medical devices in South Korea and internationally. The company offers immunology diagnostic reagents. It also provides COVID-19 kit; blood glucose monitoring system; HbA1c test machine; and Gcare LIPID and LIPID printer. Green Cross Medical Science Corporation was founded in 1972 and is headquartered in Yongin… Read more
Green Cross Medical Science Corporation (142280) - Net Assets
Latest net assets as of September 2025: ₩46.80 Billion KRW
Based on the latest financial reports, Green Cross Medical Science Corporation (142280) has net assets worth ₩46.80 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩96.65 Billion) and total liabilities (₩49.85 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩46.80 Billion |
| % of Total Assets | 48.43% |
| Annual Growth Rate | 2.72% |
| 5-Year Change | -27.01% |
| 10-Year Change | 42.77% |
| Growth Volatility | 71.23 |
Green Cross Medical Science Corporation - Net Assets Trend (2014–2024)
This chart illustrates how Green Cross Medical Science Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Green Cross Medical Science Corporation (2014–2024)
The table below shows the annual net assets of Green Cross Medical Science Corporation from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩41.21 Billion | +11.62% |
| 2023-12-31 | ₩36.92 Billion | +11.03% |
| 2022-12-31 | ₩33.25 Billion | -7.92% |
| 2021-12-31 | ₩36.11 Billion | -36.04% |
| 2020-12-31 | ₩56.47 Billion | +13.90% |
| 2019-12-31 | ₩49.58 Billion | +223.18% |
| 2018-12-31 | ₩15.34 Billion | -33.97% |
| 2017-12-31 | ₩23.23 Billion | -13.46% |
| 2016-12-31 | ₩26.85 Billion | -6.99% |
| 2015-12-31 | ₩28.87 Billion | -8.37% |
| 2014-12-31 | ₩31.50 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Green Cross Medical Science Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 72.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩4.12 Billion | 9.98% |
| Common Stock | ₩10.87 Billion | 26.38% |
| Other Components | ₩26.23 Billion | 63.64% |
| Total Equity | ₩41.21 Billion | 100.00% |
Green Cross Medical Science Corporation Competitors by Market Cap
The table below lists competitors of Green Cross Medical Science Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
H.H.Galaxy Co., Ltd.
TWO:2949
|
$25.64 Million |
|
Taiwan Name Plate Co. Ltd.
TWO:6593
|
$25.65 Million |
|
PT Wijaya Karya (Persero) Tbk
F:5AA
|
$25.67 Million |
|
DIVA Laboratories Ltd
TWO:4153
|
$25.67 Million |
|
EVERCHINA INT.HDGS.
F:ICHA
|
$25.64 Million |
|
Thantawan Industry Public Company Limited
BK:THIP
|
$25.64 Million |
|
Cobre Ltd
AU:CBE
|
$25.64 Million |
|
Berjaya Assets Bhd
KLSE:3239
|
$25.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Green Cross Medical Science Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 34,499,150,510 to 41,214,438,830, a change of 6,715,288,320 (19.5%).
- Net income of 3,581,069,030 contributed positively to equity growth.
- Other factors increased equity by 3,134,219,290.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩3.58 Billion | +8.69% |
| Other Changes | ₩3.13 Billion | +7.6% |
| Total Change | ₩- | 19.47% |
Book Value vs Market Value Analysis
This analysis compares Green Cross Medical Science Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.89x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.44x to 1.89x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩2482.17 | ₩3585.00 | x |
| 2017-12-31 | ₩2086.07 | ₩3585.00 | x |
| 2018-12-31 | ₩1377.33 | ₩3585.00 | x |
| 2019-12-31 | ₩2353.26 | ₩3585.00 | x |
| 2020-12-31 | ₩2680.28 | ₩3585.00 | x |
| 2021-12-31 | ₩1714.26 | ₩3585.00 | x |
| 2022-12-31 | ₩1577.38 | ₩3585.00 | x |
| 2023-12-31 | ₩1636.40 | ₩3585.00 | x |
| 2024-12-31 | ₩1898.68 | ₩3585.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Green Cross Medical Science Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.69%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.45%
- • Asset Turnover: 1.18x
- • Equity Multiplier: 2.13x
- Recent ROE (8.69%) is above the historical average (-13.16%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 11.80% | 4.57% | 1.56x | 1.65x | ₩566.58 Million |
| 2015 | 2.53% | 0.82% | 1.23x | 2.52x | ₩-2.16 Billion |
| 2016 | -7.04% | -2.19% | 1.35x | 2.37x | ₩-4.58 Billion |
| 2017 | -5.80% | -1.37% | 1.63x | 2.61x | ₩-3.67 Billion |
| 2018 | -69.82% | -12.41% | 1.35x | 4.17x | ₩-12.24 Billion |
| 2019 | -32.69% | -17.22% | 1.06x | 1.79x | ₩-21.16 Billion |
| 2020 | 11.90% | 5.92% | 1.07x | 1.87x | ₩1.07 Billion |
| 2021 | -58.71% | -20.85% | 1.06x | 2.65x | ₩-24.81 Billion |
| 2022 | -10.77% | -3.17% | 1.17x | 2.90x | ₩-6.91 Billion |
| 2023 | 5.21% | 1.91% | 1.04x | 2.62x | ₩-1.65 Billion |
| 2024 | 8.69% | 3.45% | 1.18x | 2.13x | ₩-540.37 Million |
Industry Comparison
This section compares Green Cross Medical Science Corporation's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Green Cross Medical Science Corporation (142280) | ₩46.80 Billion | 11.80% | 1.07x | $25.64 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |